MSMohamed Sharief

Mohamed Sharief

*This is an algorithmically generated author record based on publicly available information.

Mohamed Sharief has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Imaging‐Guided Versus Conventional Ventricular Tachycardia Ablation in Ischemic Cardiomyopathy: A Systematic Review and Meta‐Analysis

    by Sabbir Ahmed, Khalid Sawalha, Mohamed Sharief, Ahmed Ammar

    Advanced cardiac imaging can characterize infarct substrate and guide ablation strategy and lesion delivery during ventricular tachycardia (VT) ablation, but its incremental benefit over conventional strategies in ischemic cardiomyopathy (ICM) remains uncertain. We compared imaging‐guided with conventional VT ablation in adults with ICM. This PRISMA‐compliant systematic review and meta‐analysis was registered in PROSPERO (CRD420261399180). MEDLINE, Cochrane CENTRAL, and Scopus were searched from January 1, 2016, through May 21, 2026, with citation tracking. Comparative analyses were restricted to ICM populations or extractable ICM subgroups. The primary outcome was VT recurrence, pooled using random‐effects risk ratios (RRs); single‐arm imaging‐guided cohorts were summarized descriptively. Four comparative studies included 316 patients, of whom 134 underwent imaging‐guided ablation and 182 underwent conventional ablation. Imaging‐guided ablation was associated with lower VT recurrence (pooled RR 0.53, 95% confidence interval 0.36–0.79; p = 0.002; I 2 = 0%), with consistent effects across imaging modalities and study designs. Major complications were infrequent and numerically similar between groups, although sparse events and heterogeneous definitions precluded pooling. Three additional single‐arm imaging‐guided studies reported favorable VT‐free or event‐free survival, acceptable safety, and high acute non‐inducibility, but were not used to infer comparative efficacy. In patients with ICM undergoing scar‐related VT ablation, imaging‐guided ablation was associated with lower VT recurrence without an apparent increase in major complications; given the limited comparative evidence, these findings are hypothesis‐generating rather than practice‐changing. Larger multicenter randomized trials are required to confirm the magnitude of benefit and define patient selection, imaging modality, and integration strategy.

  • Open Access

    Primary prevention implantable cardioverter-defibrillator use in non-ischemic dilated cardiomyopathy based on arrhythmic risk stratification and left ventricular reverse remodeling prediction

    by Ahmed Muhammed, Mohamed Abdelazeem, Mohamed Gamaleldin Elewa, Mohamed Sharief, Ahmed Ammar

    Sudden cardiac death (SCD) and significant ventricular arrhythmias in patients with dilated cardiomyopathy (DCM) have been markedly reduced over the last couple of decades as a result of the advances in pharmacological and non-pharmacological treatment. Primary prevention implantable cardioverter-defibrillator (ICD) plays an important role in the treatment of patients at risk of SCD caused by ventricular arrhythmias. However, the arrhythmic risk stratification in patients with DCM remains extremely challenging, and the decision for primary prevention ICD implantation based on left ventricular ejection fraction (LVEF) solely appears to be insufficient. This review provides an update on current evidence for primary prevention ICD implantation, arrhythmic risk stratification, and left ventricular reverse remodeling (LVRR) prediction in patients with DCM in addition to most recent guideline recommendations for primary prevention ICD implantation in DCM patients and a proposed multiparametric algorithm based on arrhythmic risk stratification and left ventricular reverse remodeling (LVRR) prediction to better identify patients who are likely to benefit from primary prevention ICD.